Trial Profile
A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms RE-GEND
- 07 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2021 Planned End Date changed from 10 Jul 2024 to 10 Nov 2025.
- 31 Aug 2021 Planned primary completion date changed from 10 Jul 2024 to 10 Nov 2025.